Skip to main content

Vistagen Therapeutics, Inc.

corporate_fare Company Profile

Vistagen Therapeutics, Inc.

VTGN·NASDAQ·Life Sciences·CIK 0001411685

Vistagen Therapeutics, Inc. is a late clinical-stage therapeutics company that develops and aims to commercialize new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company's neuroscience pipeline includes five clinical-stage intranasal pherine product candidates, each with a novel neurocircuitry-focused proposed mechanism of action and at least one positive clinical study in its targeted patient population. These intranasal pherine product candidates are designed to rapidly, specifically, and selectively bind to peripheral receptors in human nasal chemosensory neurons and activate neurocircuits that are believed to regulate brain areas, without requiring systemic absorption or uptake into the brain for therapeutic benefits. Vistagen Therapeutics, Inc.'s most advanced intranasal pherine product candidate, fasedienol, is currently in a U.S. Phase 3 development program for the acute treatment of social anxiety disorder. Other product candidates include itruvone, which is being developed for the treatment of major depressive disorder; refisolone, for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause; PH15, for the improvement of psychomotor impairment due to mental fatigue; and PH284, for the treatment of cancer cachexia. Social anxiety disorder affects over 30 million adults in the U.S. and typically has an onset early in life, with a reported mean duration of about 20 years.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for VTGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for VTGN spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Vistagen 10-Q: $20.0M Cash, Going Concern Doubt, Nasdaq Deadline Feb 1, 2027
  • Vistagen Cuts Quarterly Loss to $10.7M but Cash Only Funds Operations Into 2027
  • Vistagen Wins FDA Backing for LSAS Endpoint in Future Phase 3 of Fasedienol
  • Vistagen Cuts 31% of Workforce to Preserve Cash for Fasedienol Phase 3
  • Vistagen Expands Executive Severance Plan to Cover Terminations Without Change in Control

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$1.27M
Net Income
-$69.69M
Diluted EPS
-$1.83
Op. Cash Flow
-$66.44M
Operating Income
-$72.13M
Cash & Equivalents
$30.79M
Debt / Equity
0.00×
Net Margin
-54.91×
Shares Outstanding
38.07M sh
Source: 10-K · filed 2026-06-15 · accession 0001628280-26-043271

Short Interest & Short Volume

3.42 days to cover

FINRA reported short interest of 2,488,148 shares in VTGN as of the October 30, 2026 settlement, a 0.6% increase from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 34.2% of VTGN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,488,148 shares as of October 30, 2026
Change vs prior period▲ 0.6%
Days to cover3.42 at avg daily volume of 728,036
Daily short volume (FINRA facilities)34.2% of 594,822 shares on November 20, 2026
5-day average short volume43.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with V →
$0.1666 +1.83% today
52-week range · as of 2026-11-13 $0.1638 – $5.14
Market cap
$7.56M
Volume
919.9K (1.1× avg)
3-mo avg 817.4K
Live data · 2026-11-21 15:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VTGN - Latest Insights

VTGN
Nov 13, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1805
Real-time Price: $0.1666 info
Change: -$0.0139 (-8%) info
Market Cap: $7.556M info
VTGN
Nov 13, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1805
Real-time Price: $0.1666 info
Change: -$0.0139 (-8%) info
Market Cap: $7.556M info
VTGN
Nov 09, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.172
Real-time Price: $0.1666 info
Change: -$0.0054 (-3%) info
Market Cap: $7.556M info
VTGN
Oct 30, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1714
Real-time Price: $0.1666 info
Change: -$0.0048 (-3%) info
Market Cap: $7.556M info
VTGN
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2461
Real-time Price: $0.1666 info
Change: -$0.0795 (-32%) info
Market Cap: $7.556M info
VTGN
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.373
Real-time Price: $0.1666 info
Change: -$0.2064 (-55%) info
Market Cap: $7.556M info
VTGN
Sep 22, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.2644
Real-time Price: $0.1666 info
Change: -$0.0978 (-37%) info
Market Cap: $7.556M info
VTGN
Aug 14, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.270
Real-time Price: $0.1666 info
Change: -$0.1034 (-38%) info
Market Cap: $7.556M info
VTGN
Aug 14, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2732
Real-time Price: $0.1666 info
Change: -$0.1066 (-39%) info
Market Cap: $7.556M info
VTGN
Aug 14, 2026, 8:32 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.2732
Real-time Price: $0.1666 info
Change: -$0.1066 (-39%) info
Market Cap: $7.556M info
VTGN
Aug 04, 2026, 5:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.321
Real-time Price: $0.1666 info
Change: -$0.1544 (-48%) info
Market Cap: $7.556M info
VTGN
Jun 30, 2026, 8:28 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.260
Real-time Price: $0.1666 info
Change: -$0.0934 (-36%) info
Market Cap: $7.556M info
VTGN
Jun 30, 2026, 8:28 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.260
Real-time Price: $0.1666 info
Change: -$0.0934 (-36%) info
Market Cap: $7.556M info
VTGN
Jun 17, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6681
Real-time Price: $0.1666 info
Change: -$0.5015 (-75%) info
Market Cap: $7.556M info
VTGN
Jun 15, 2026, 4:50 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.570
Real-time Price: $0.1666 info
Change: -$0.4034 (-71%) info
Market Cap: $7.556M info
VTGN
Jun 15, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5703
Real-time Price: $0.1666 info
Change: -$0.4037 (-71%) info
Market Cap: $7.556M info
VTGN
Jun 15, 2026, 4:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.572
Real-time Price: $0.1666 info
Change: -$0.4054 (-71%) info
Market Cap: $7.556M info
VTGN
Jun 09, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.552
Real-time Price: $0.1666 info
Change: -$0.3854 (-70%) info
Market Cap: $7.556M info
VTGN
Jun 09, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.552
Real-time Price: $0.1666 info
Change: -$0.3854 (-70%) info
Market Cap: $7.556M info
VTGN
May 19, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.630
Real-time Price: $0.1666 info
Change: -$0.4634 (-74%) info
Market Cap: $7.556M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets